300888 稳健医疗
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,909,017-18.84%8,185,02211,351,3328,037,42112,533,946
减:营业总成本1,707,213-9.45%7,285,3449,119,6886,727,8577,829,145
    其中:营业成本999,874-13.31%4,174,5975,972,8014,028,2475,070,422
               财务费用(14,601)-16.82%(61,859)(122,575)(107,499)218,641
               资产减值损失(17,745)-81.32%(393,762)(362,869)(100,665)(240,187)
公允价值变动收益14,430-68.72%46,67832,14958,47411,179
投资收益14,68617.09%127,34351,471103,23821,585
    其中:对联营企业和合营企业的投资收益61-93.53%1,5824,6983,5264,566
营业利润226,274-50.02%817,9701,976,5501,475,6404,531,737
利润总额223,761-50.62%749,8461,919,5061,462,7614,502,459
减:所得税费用30,248-53.62%121,301245,169225,316679,910
净利润193,513-50.12%628,5451,674,3371,237,4453,822,549
减:非控股权益11,0880.78%48,14223,620(1,875)12,137
股东净利润182,425-51.60%580,4031,650,7171,239,3203,810,413

市场价值指针
每股收益 (元) *0.310-51.56%0.9802.7902.9109.800
每股派息 (元) *----0.5001.9000.9001.800
每股净资产 (元) *19.672-30.70%19.40427.44425.03024.511
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容